Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 3/20 | 0.37 |
| ▸ | FLT3 | P36888 | 3/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.34 |
| ▸ | NAMPT | P43490 | 2/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 3/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.32 |
| ▸ | KDM6B | O15054 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2905250 | 1.00 | HCAR3 (0.40) | HCAR3HCAR2CDK4FLT3FFAR4 | |
| SCHEMBL3057601 | 1.00 | HCAR3 (0.40) | HCAR3HCAR2CDK4FLT3FFAR4 | |
| SCHEMBL2905252 | 0.74 | EDNRB (0.34) | CDK4FLT3PDK2 | |
| SCHEMBL2910754 | 0.74 | EDNRB (0.34) | CDK4FLT3PDK2 | |
| SCHEMBL4214600 | 0.72 | HCAR3 (0.45) | HCAR3HCAR2CDK4FFAR4ESR1 | |
| SCHEMBL2910573 | 0.68 | KDM4E (0.41) | — | |
| SCHEMBL2910571 | 0.68 | KDM4E (0.41) | — | |
| SCHEMBL2913101 | 0.68 | KDM4E (0.41) | — | |
| SCHEMBL15880089 | 0.66 | TP53 (0.32) | CDK4FLT3PDK2 | |
| SCHEMBL3066827 | 0.65 | PIK3CA (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | HTR2C, HTR5A, HTR3C | HCAR3 430/4885HCAR2 188/4885CDK4 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.